NCT01705288

Brief Summary

Over 600,000 hysterectomies are performed annually in the United States. Despite increasing use of less invasive approaches, the majority of hysterectomies are still performed via traditional laparotomy, which can be associated with generally slower recovery and longer lengths of post-operative hospitalization. Rapid Recovery Protocols (RRP) seek to optimize post-surgical morbidity outcomes by returning a patient to normal physiology as quickly as possible following surgery.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
103

participants targeted

Target at P75+ for early_phase_1

Timeline
Completed

Started Jan 2013

Typical duration for early_phase_1

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 9, 2012

Completed
3 days until next milestone

First Posted

Study publicly available on registry

October 12, 2012

Completed
3 months until next milestone

Study Start

First participant enrolled

January 1, 2013

Completed
3.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 24, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 24, 2016

Completed
3.5 years until next milestone

Results Posted

Study results publicly available

February 17, 2020

Completed
Last Updated

February 17, 2020

Status Verified

February 1, 2020

Enrollment Period

3.6 years

First QC Date

October 9, 2012

Results QC Date

February 4, 2020

Last Update Submit

February 4, 2020

Conditions

Keywords

laparotomyhysterectomy

Outcome Measures

Primary Outcomes (1)

  • Hospital Stay

    Length of hospital stay for patients undergoing laparotomy on the gynecologic oncology service measured as whole days from the day of surgery until discharge

    1 Month

Secondary Outcomes (2)

  • Pain Medications Used

    Post operative - day 2

  • Pain Assessment

    Day 0

Study Arms (2)

Control Group (Standard Laparotomy)

ACTIVE COMPARATOR

Patients undergoing standard anesthesia and standard exploratory laparotomy. Treatment will be per your surgeon's routine standards.

Procedure: LaparotomyDrug: intravenous narcoticsDrug: standard anesthesia

Rapid Recovery Group

EXPERIMENTAL

Protocol for "rapid recovery laparotomy" procedure involves pre-operative counseling, the use of regional anesthesia (spinal or epidural pain management rather than intravenous narcotics), post-operative use of non-steroidal anti-inflammatory drugs, early eating after surgery, early walking, and certain goals for discharge from the hospital.

Procedure: LaparotomyDrug: regional anesthesiaDrug: Non-steroidal anti-inflammatory drugs

Interventions

LaparotomyPROCEDURE

Exploratory surgery for gynecologic diagnosis.Involves pre-operative counseling, the use of regional anesthesia (spinal or epidural pain management rather than intravenous narcotics), early eating after surgery, early walking, and certain goals for discharge from the hospital

Control Group (Standard Laparotomy)Rapid Recovery Group

given for pain management after surgery per physician orders

Also known as: morphine
Control Group (Standard Laparotomy)

inhalant or intravenous during surgery

Also known as: general anesthesia
Control Group (Standard Laparotomy)

given by spinal or epidural infusion

Also known as: local anesthesia
Rapid Recovery Group

given for pain management after surgery

Also known as: NSAIDs
Rapid Recovery Group

Eligibility Criteria

Age19 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Women who are being seen at the Women's Health Center by the Gynecologic Oncology group at the University of Minnesota if planned surgery includes an exploratory laparotomy

You may not qualify if:

  • \< 19 years old
  • Pregnant
  • Undergoing a procedure other than laparotomy
  • Scheduled to be discharged the same day of surgery
  • Chronic narcotic pain medication user
  • American Society of Anesthesiologists (ASA) score of \> or = 3
  • Any condition that would exclude women from undergoing regional anesthesia

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Masonic Cancer Center, University of Minnesota

Minneapolis, Minnesota, 55455, United States

Location

Related Publications (2)

  • Chau JPC, Liu X, Lo SHS, Chien WT, Hui SK, Choi KC, Zhao J. Perioperative enhanced recovery programmes for women with gynaecological cancers. Cochrane Database Syst Rev. 2022 Mar 15;3(3):CD008239. doi: 10.1002/14651858.CD008239.pub5.

  • Dickson EL, Stockwell E, Geller MA, Vogel RI, Mullany SA, Ghebre R, Witherhoff BJ, Downs LS Jr, Carson LF, Teoh D, Glasgow M, Gerber M, Rivard C, Erickson BK, Hutchins J, Argenta PA. Enhanced Recovery Program and Length of Stay After Laparotomy on a Gynecologic Oncology Service: A Randomized Controlled Trial. Obstet Gynecol. 2017 Feb;129(2):355-362. doi: 10.1097/AOG.0000000000001838.

MeSH Terms

Conditions

Uterine Cervical NeoplasmsEndometrial NeoplasmsOvarian Neoplasms

Interventions

LaparotomyMorphineAnesthesia, GeneralAnesthesia, ConductionAnesthesia, LocalAnti-Inflammatory Agents, Non-Steroidal

Condition Hierarchy (Ancestors)

Uterine NeoplasmsGenital Neoplasms, FemaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsUterine Cervical DiseasesUterine DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital DiseasesEndocrine Gland NeoplasmsOvarian DiseasesAdnexal DiseasesEndocrine System DiseasesGonadal Disorders

Intervention Hierarchy (Ancestors)

Surgical Procedures, OperativeMorphine DerivativesMorphinansOpiate AlkaloidsAlkaloidsHeterocyclic CompoundsHeterocyclic Compounds, Bridged-RingHeterocyclic Compounds, 4 or More RingsHeterocyclic Compounds, Fused-RingPhenanthrenesPolycyclic Aromatic HydrocarbonsPolycyclic CompoundsAnesthesiaAnesthesia and AnalgesiaAnalgesics, Non-NarcoticAnalgesicsSensory System AgentsPeripheral Nervous System AgentsPhysiological Effects of DrugsPharmacologic ActionsChemical Actions and UsesAnti-Inflammatory AgentsTherapeutic UsesAntirheumatic Agents

Results Point of Contact

Title
Dr. Peter Argenta
Organization
Masonic Cancer Center at University of Minnesota

Study Officials

  • Peter Argenta, M.D.

    Masonic Cancer Center, University of Minnesota

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
early phase 1
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 9, 2012

First Posted

October 12, 2012

Study Start

January 1, 2013

Primary Completion

August 24, 2016

Study Completion

August 24, 2016

Last Updated

February 17, 2020

Results First Posted

February 17, 2020

Record last verified: 2020-02

Locations